Vaxcyte kompaniyasidagi eng so‘nggi ish o‘rinlari

Vaxcyte is a clinical-stage vaccine biotechnology company developing vaccines against serious bacterial infections. Its pipeline includes broad-spectrum pneumococcal conjugate candidates VAX-31 and VAX-24, alongside earlier-stage programs for Group A Streptococcus and Shigella. The company combines synthetic chemistry with a cell-free protein synthesis platform licensed from Sutro Biopharma to produce complex protein antigens. Its research and development work focuses on preventing invasive disease and addressing the consequences of antibiotic resistance, particularly for vulnerable populations.